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Abstract. Carcinomas of unknown primary origin account 
for 3-5% of all malignancies. The current literature suggests 
that metastatic dissemination is able to occur in the absence 
of primary tumor growth. In metastatic disease that is difficult 
to diagnose, the origin usually remains unknown even after 
an exhaustive evaluation of immunohistochemistry (IHC) 
markers. In the current study, a 49-year-old male presented 
with lymph nodes metastases of unknown origin. The exci-
sional biopsy of an inguinal node revealed an adenocarcinoma 
growth pattern, but the IHC could not determine the primary 
origin. A gene profiling test was performed to complete the 
diagnosis and a salivary gland adenocarcinoma was diagnosed 
with 90% probability. Subsequently, the patient underwent 
appropriate chemotherapy for salivary gland adenocarcinoma, 
and exhibited an improved partial response. The present case 
study highlights the importance of an accurate diagnosis of the 
primary tumor and the use of all the current tools available in 
order to provide patients with the best treatment possible.
Introduction
Cancers of unknown primary (CUPs) represent a heterogeneous 
group of metastatic tumors for which the site of origin cannot 
be diagnosed on a standardized diagnostic work-up at the time 
of diagnosis. CUP accounts for 3-5% of all malignancies (1,2).
At present, CUP is the fifth and eighth most common 
cancer diagnosis in women and men, respectively (3). The 
majority of cases have an unfavourable prognosis, with a life 
expectancy that ranges from 6 to 9 months (4).
Without a specific diagnosis, the management of these 
patients is more difficult, as the treatment is typically empirical, 
with non‑specific antineoplastic drugs used in combination in 
a range of chemotherapy regimens, but with no one treatment 
schedule superior to the others (5).
Primary tumor cells exhibit characteristic genetic expres-
sion that is maintained among the metastatic cells; therefore, 
it is possible to identify the primary site by comparing the 
genetic profile of the metastatic cells to a genetic profile 
database of different types of tumors. Therefore, various gene 
expression profiling methods have been developed in order to 
aid in identifying the primary tumor (6).
The current study presents the case of a patient with a 
diagnosis of CUP in which gene expression profiling was 
performed and the patient benefited from a specific systemic 
chemotherapy treatment, established as a result of having 
taken into account this information of the presumed primary 
site. Written informed consent was obtained from the patient.
Case report 
A 49-year-old male, non-smoker, with no notable medical 
history, was admitted to the Miguel Servet University Hospital 
(Zaragoza, Spain) in September 2013 due to right inguinal 
pain and swelling of the ipsilateral leg. The patient had a good 
performance status of 1 and a normal physical examination, 
with the exception of the swelling of the right leg. Inguinal 
ultrasonography (US) did not reveal any pathology. Since 
no symptom improvement was achieved over time, US was 
performed again in February 2014, which revealed multiple 
enlarged abdominal lymph nodes, including retroperitoneal 
and para-aortic nodes, the largest measuring 32 mm in diam-
eter. 
Total body computed tomography (CT) and fluorode-
oxyglucose positron emission CT were performed and a 
poliadenopathic condition, involving the left axillary, cervical, 
supraclavicular, mediastinal, retroperitoneal, para-aortic, iliac 
and bilateral inguinal lymph nodes, was found. The largest 
node, in the right inguinal area, measured 41 mm at its largest 
diameter.
Laboratory tests revealed a markedly increased 
carcinoembryonic antigen (CEA) level (33 U/ml; normal 
range for non-smokers, 0-2.5 U/ml; normal range for 
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smokers, 0-5 U/ml), but the α-fetoprotein, β-human chori-
onic gonadotropin, prostate‑specific antigen (PSA), cancer 
antigen 19.9 and β2 microglobulin levels were within labora-
tory normal ranges. On March 3, 2014, the patient underwent 
an excisional biopsy of the right inguinal lymph node. 
The pathology report showed an adenocarcinoma, without 
identifying the primary site. An extensive range of immuno-
histochemistry (IHC) tests were performed, which resulted in 
positivity for cytokeratin (CK)7, CK8, CAM5.2, CEA, epithe-
lial membrane antigen (EMA), AE1:AE3, E-cadherin and 
GDFP-15, and negativity for ALC, S-100, vimentin, PLAP, 
inhibin, cluster of differentiation 30, CK20, CK5/6, PSA, 
thyroid transcription factor-1, CDX-2, RE, RP and human 
epidermal growth factor-2 (Table I). No EGFR gene mutation 
was found. The Ki-67 proliferation index was 70%.
This IHC profile suggested the lungs, breasts, salivary 
glands and sweat glands as the most likely primary tumor 
locations. In order to select the most adequate therapy, a tumor 
gene expression profiling test was performed. This novel 
diagnostic technique allows the prediction of the tumor origin 
based on gene expression patterns that are retained from the 
tissues of origin (7). A salivary gland adenocarcinoma was the 
main diagnosis with a probability of 90%. Breast adenocar-
cinoma could not be excluded, with a probability of 6%. The 
patient received standard advanced salivary gland first‑line 
chemotherapy consisting of a 50mg/m2 cisplatin, 50mg/m2 
doxorubicin and 500mg/m2 cyclofosfamide (CAP) regimen 
every three weeks.
After 6 cycles of CAP for 18 weeks, CT revealed a partial 
response of all the lymph nodes, with a significant decrease 
Figure 1. Left axillary lymph-node (A) prior to and (B) following chemotherapy.
Figure 2. Mediastinal lymph-node (A) prior to and (B) following chemotherapy.
Table I. Immunohistochemistry results.
Result Antigen
Positivity CK7, CK8, CAM5.2, CEA, EMA, AE1:AE3, E-cadherin, GDFP-15
Negativity CD45, S-100, vimentin, PLAP, inhibin, CD30, CK20, CK5/6, PSA, TTF1, CDX2, RE, RP, HER2
CK, cytokeratin; CAM5.2, anti-cytokeratin 5.2; CEA, carcinoembryonic antigen; EMA, epithelial membrane antigen; AE, anti-pan cytokeratin; 
GDFP‑15, gross cystic disease fluid protein‑15; PLAP, anti‑placental alkaline phosphatase antibody; CD, cluster of differentiation; PSA, 
prostate‑specific antigen; TTF1, thyroid transcription factor‑1; CDX2, caudal‑type homeobox protein; RE, estrogen receptor; RP, progesterone 
receptor; HER2, human epidermal growth factor-2.
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in size of the left axillary, mediastinal and right inguinal 
lymph nodes (Figs. 1-3). Subsequently, the patient continued 
follow-up with stable disease until Februrary 2015, when 
progression occurred (brain and liver metastases). Two 
different regimens of chemotherapy (carboplatin-taxol and 
vinorelbine) were administered with no response. In July 2015, 
the patient presented a worsened performance status and was 
admitted due to seizures.
Discussion
By definition, CUP is a histologically confirmed malignant 
tumor that is not compatible with a primary neoplasm in the 
biopsy area, and which has an origin that remains unclear once 
a thorough clinical history, complete physical examination and 
basic complementary studies have been performed (8).
CUP can be classified as an adenocarcinoma (50‑70%), 
poorly-differentiated carcinoma (20-30%), squamous cell 
carcinoma (5-8%) or undifferentiated malignant neoplasm 
(2-3%) depending on its histological characteristics (9,10).
There is little published data on adenocarcinomas of 
unknown origin with lymphadenopathy presentation. The 
majority of the studies published describe mediastinal 
and cervical lymph node presentations (11-14). Different 
approaches have been used for treatment; in one approach, 
surgery is the cornerstone of the treatment, whereas in another, 
platinum-based chemotherapy is used, with progression-free 
survival times of 38 and 30 months, respectively (11,14).
Recent advances made with regard to specific treatments 
for each cancer type together with the continuous development 
of novel therapies should benefit the primary tumor predic-
tion in patients with CUP, providing improved therapies and 
prognosis. 
Traditionally, the majority of patients have been treated 
with empiric chemotherapy, including platinum- and 
taxane-based chemotherapy regimes, with poor results 
(median survival time, 6-8 months) (15,16). As randomised 
controlled trials have not established any effective therapies 
for such patients, empirical systemic treatments that consider 
the performance status of the patients are widely accepted. 
In recent years, novel targeted drugs and personalized medi-
cine have had increasing roles in oncological therapy. As a 
result, with more specific and targeted drugs, therapy with a 
single empiric combination chemotherapy regimen becomes 
increasingly inadequate.
Gene expression profiling assays correctly identified the 
site of origin in 85% of cases in blinded studies of tumors of 
known origin, and was found to favorably compare with IHC 
staining (17,18). The best use of gene expression profiling to 
form a diagnosis appears to be for cases with inconclusive 
IHC staining. The site‑specific treatment of carcinomas of 
unknown primary site based on gene expression profiling 
and/or IHC predictions appears to result in improvements in 
the overall patient outcome (19,20). Therefore, gene expres-
sion profiling should be included in the diagnosis of a patient 
when IHC staining is not able to predict a single site of origin. 
Site‑specific treatment, based on a tissue of origin diagnosis, 
should replace empiric chemotherapy in patients with CUP.
Salivary gland cancer (SGC), such as that diagnosed 
in the present case, is uncommon and accounts for <5% 
of all cancers of the head and neck (21). Different types 
of SGC have considerably variable histological patterns 
and behavior. The tumors are classified according to the 
2005 World Health system (22), in which 24 histological 
subtypes are listed. In total, >75% of all SGCs are accounted 
for by mucoepidermoid carcinoma, adenoid cystic carci-
noma and adenocarcinoma, as described by the Memorial 
Sloan-Kettering experience (23). The characteristics of slow 
growth, multiple local recurrences and prolonged clinical 
course, often with delayed distant metastasis, have all been 
attributed to SGCs (23).
Salivary gland malignancies may exhibit distant metastatic 
disease, with the best example data shown in studies of adenoid 
cystic carcinoma. The most common site of distant metastasis 
is the lungs (24), followed by the liver and bones.
Metastatic presentation of unknown primary is uncommon 
for salivary gland carcinomas. Florentine et al (25) reported 
a patient who had metastatic bone disease from unknown 
primary as the initial diagnosis, and the patient's further 
medical history showed a record of early-stage adenoid cystic 
carcinoma (ACC) of the soft palate, which had been diagnosed 
and resected 3 months earlier. The bone histopathology was 
compatible with ACC.
To the best of our knowledge, the present study is the first 
report of multiple lymph nodes metastases as the only presen-
tation in salivary gland adenocarcinoma.
Figure 3. Right inguinal lymph-node (A) prior to and (B) following chemotherapy.
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CAP, the most commonly studied regimen for cancer, 
is an actively used regimen for SGC (26-28). In a study by 
Alberts et al (29) responses were observed that included 
2 patient who experienced complete remission, from a 
total of 5 patients. Kaplan et al (26) recorded 5 objective 
responses, including 1 complete response, from a total of 
6 patients. Additionally, 3 complete and 3 partial remissions, 
from a total of 13 patients, were reported in the study by 
Dreyfuss et al (27).
The present patient benefited from a site‑specific treat-
ment; however, if the primary site had not been known, a 
different regimen of chemotherapy would have had been 
used and since no optimum chemotherapy regimen has 
been identified for CUP, a worse patient outcome would 
be expected (30). The patient underwent gene expression 
profiling with CancerTYPE ID (BioTheranostics, Inc., San 
Diego, CA, USA), in order to aid in the identification of the 
primary site. The CancerTYPE ID assay is a 92-gene reverse 
transcription-polymerase chain reaction assay that allows the 
identification of 30 main tumor types and 54 subtypes (17). 
There is also another gene expression profiling assay currently 
commercially available, which uses 64 tissue-specific 
microRNAs to enable the identification of 42 tumor types, 
using a microarray technology known as the Cancer Origin 
Test (Rosetta Genomics, Rehovot, Israel) (18). These two 
assays were validated using biopsies of tumors from known 
primary sites. Biopsies were taken from either the primary 
site or a metastatic site; tumors with well-differentiated 
and poorly-differentiated histology were included. In these 
validation studies, each of which included specimens from 
several hundred tumors, the two assays each correctly identi-
fied 85% of the tumors included (17,18).
Regarding the present case study, the patient benefited from 
a site‑specific treatment according to the prediction of the gene 
expression profiling assay, and experienced a partial response for 
all lesions following use of a chemotherapy widely used in salivary 
gland adenocarcinoma. Gene expression profiling is a valu-
able addition to a diagnostic evaluation. Nevertheless, ongoing 
clinical trials are required to refine these recommendations.
References
 1. Pavlidis N and Fizazi K: Cancer of unknown primary (CUP). 
Crit Rev Oncol Hematol 54: 243-250, 2005.
 2. Varadhachary GR, Abbruzzese JL and Lenzi R: Diagnostic 
strategies for unknown primary cancer. Cancer 100: 1776-1785, 
2004.
 3. Altman E and Cadman E: An analysis of 1539 patients with 
cancer of unknown primary site. Cancer 57: 120-124, 1986.
 4. Pavdilis N, Briasoulis E, Hainsworth J and Greco FA: Diagnostic 
and therapeutic management of cancer of an unknown primary. 
Eur J Cancer 30: 1990-2005, 2003.
 5. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, 
Ioannidis JP and Pavlidis N: Comparative survival with diverse 
chemotherapy regimens for cancer of unknown primary site: 
Multiple-treatments meta-analysis. Cancer Treat Rev 35: 
570-573, 2009.
 6. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, 
Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, et al: Molecular 
profiling of carcinoma of unknown primary and correlation with 
clinical evaluation. J Clin Oncol 26: 4442-4448, 2008.
 7. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, 
Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr and 
Hampton GM: Molecular classification of human carcinoma by 
use of gene expression signatures. Cancer Res 61: 7388-7393, 
2001.
 8. Greco FA and Hainsworth JD: Cancer of unknown primary site. 
In: Cancer: Principles & Practice of Oncology. DeVita VT Jr, 
Hellman S and Rosenberg SA (eds). 6th edition. Lippincott 
Williams & Wilkins, Philadelphia, pp2537-2560, 2001.
 9. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW and 
Hillen HF: Epidemiology of unknown primary tumours; incidence 
and population-based survival of 1285 patients in Southeast 
Netherlands, 1984-1992. Eur J Cancer 38: 409-413, 2002.
10. Hess KR, Abbruzzese MC, Lenzi R, Raber MN and 
Abbruzzese JL: Classification and regression tree analysis of 
1000 consecutive patients with unknown primary carcinoma. 
Clin Cancer Res 5: 3403-3410, 1999.
11. Harada H, Yamashita Y, Kuraoka K and Taniyama K: 
Sequential mediastinal lymphadenectomy of an unknown 
primary tumor. The Ann Thorac Surg 95: 687-689, 2013.
12. Nakano T, Endo S, Endo T, Hasegawa T, Nakayama M, 
Sugiyama Y and Hironaka M: Multimodal treatment for multi-
station mediastinal lymph node adenocarcinoma: A case report. 
Ann Thorac Cardiovasc Surg 18: 136-139, 2012.
13. Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, 
Malhaire C, Deux JF, Brun B, Piedbois P and Rahmouni A: 
Adenocarcinomas of unknown primary (ACUP) of the medi-
astinum mimicking lymphoma: CT findings at diagnosis and 
follow-up. Eur J Radiol 59: 42-48, 2006.
14. Pepper C, Pai I, Hay A, Deery A, Wilson P, Williamson P 
and Pitkin L: Investigation strategy in the management of 
metastatic adenocarcinoma of unknown primary presenting 
as cervical lymphadenopathy. Acta Otolaryngol 134: 838-842, 
2014.
15. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, 
Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P 
and Pavlidis N: Carboplatin plus paclitaxel in unknown 
primary carcinoma: A phase II Hellenic cooperative oncology 
group study. J Clin Oncol 18: 3101-3107, 2000.
16. Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, 
Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, 
et al: Cisplatin in combination with either gemcitabine or 
irinotecan in carcinomas of unknown primary site: Results of 
a randomized phase II study-trial for the French study group 
on carcinomas of unknown primary (GEFCAPI 01). J Clin 
Oncol 21: 3479-3482, 2003.
17. Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R and 
Schnabel CA: Performance and clinical evaluation of the 
92‑gene real‑time PCR assay for tumor classification. J Mol 
Diagn 13: 493-503, 2011.
18. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, 
Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, 
et al: A second-generation microRNA-based assay for diag-
nosing tumor tissue origin. Oncologist 17: 801-812, 2012.
19. Greco FA, Lennington WJ, Spigel DR, Varadhachary GR 
and Hainsworth JD: Carcinoma of unknown primary site: 
Outcomes in patients with a colorectal molecular profile 
treated with site-specific chemotherapy. J Cancer Ther 3: 
37-43, 2012.
20. Hainsworth JD, Schnabel CA, ErlanderMG, Erlander MG, 
Haines DW III and Greco FA: A retrospective study of 
treatment outcomes in patients with carcinoma of unknown 
primary site and a colorectal cancer molecular profile. Clin 
Colorectal Cancer 11: 112-118, 2012.
21. Laurie SA and Licitra L: Systemic therapy in the palliative 
management of advanced salivary gland cancers. J Clin 
Oncol 24: 2673-2678, 2006.
22. Barnes L, Eveson JW, Reichart P and Sidransky D (eds): 
Tumours of the Salivary Glands. In: World Health Organization 
Classification of Tumors: Pathology and Genetics of Head and 
Neck Tumours. World Health Organization, Lyon, France, 
pp209-282, 2005.
23. Spiro RH: Salivary neoplasms: Overview of a 35-year expe-
rience with 2,807 patients. Head Neck Surg 8: 177-184, 1986.
24. Hamper K, Lazar F, Dietel M, Caselitz J, Berger J, Arps H, 
Falkmer U, Auer G and Seifert G: Prognostic factors for 
adenoid cystic carcinoma of the head and neck: A retrospective 
evaluation of 96 cases. J Oral Pathol Med 19: 101-107, 1990.
25. Florentine BD, Fink T, Avidan S, Braslavsky D, Raza A and 
Cobb CJ: Extra-salivary gland presentations of adenoid cystic 
carcinoma: A report of three cases. Diagn Cytopathol 34: 
491-494, 2006.
26. Kaplan MJ, Johns ME and Cantrell RW: Chemotherapy 
for salivary gland cancer. Otolaryngol Head Neck Surg 95: 
165-170, 1986.
ONCOLOGY LETTERS  10:  2657-2661,  2015 2661
27. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr 
and Miller D: Cyclophosphamide, doxorubicin and cisplatin 
combination chemotherapy for advanced carcinomas of 
salivary gland origin. Cancer 60: 2869-2872, 1987.
28. Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, 
Demicheli R and Molinari R: Cisplatin, doxorubicin and cyclo-
phosphamide in advanced salivary gland carcinoma: A phase 
II trial of 22 patients. Ann Oncol 7: 640-642, 1996.
29. Alberts DS, Manning MR, Coulthared SW, Koopmann CF Jr 
and Herman TS: Adriamycin/cis-platinum/cyclophosphamide 
combination chemotherapy for advanced carcinoma of the 
parotid gland. Cancer 47: 645-648, 1981.
30. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, 
Ioannidis JP and Pavlidis N: Comparative survival with diverse 
chemotherapy regimens for cancer of unknown primary site: 
Multiple-treatments meta-analysis. Cancer Treat Rev 35: 
570-573, 2009.
